ESMO / ECC Conference Coverage

Clovis Oncology Announces First Patient Enrolled In The Phase 2 Portion Of The LIO-1 Trial Evaluating The Combination Of Lucitanib And Opdivo In Gynecologic Cancers

(Clovis Oncology) Aug 5, 2020 - Clovis Oncology, Inc. announced today treatment of the first patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis’ investigational angiogenesis inhibitor, including vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), and Opdivo® (nivolumab), Bristol Myers Squibb’s PD-1 inhibitor, for the treatment of gynecologic cancers.

read corporate press release

Natera Announces Clinical Data at ESMO GI Supporting Personalized ctDNA Testing for Oligometastatic Colorectal Cancer (CRC) Patients

(Morningstar) July 7, 2020 - Studies show Signatera's accuracy in identifying 100% of stage IV oligometastatic CRC patients in a pre-surgical setting, and the clinical utility of Signatera in optimizing post-surgical treatment decisions for patients with Stage II-III CRC and stage IV oligometastatic CRC.

read article

Maintenance Olaparib In Elderly Patients With A Germline BRCA Mutation and Metastatic Pancreatic Cancer

(ESMO) July 1, 2020 - Results from an additional analyses of phase III POLO trial by age group presented at ESMO World GI 2020 Virtual. Safety of maintenance olaparib in patients with a germline BRCA1 and/or BRCA2 mutation and metastatic pancreatic cancer is consistent irrespective of age.

read article

Ipsen Presents Phase I/II Clinical Data Evaluating liposomal irinotecan (Onivyde®) as an Investigational First-Line Combination Treatment for Metastatic Pancreatic Cancer at the ESMO World Congress on Gastrointestinal Cancer

(Yahoo! Finance) July 1, 2020 - Ipsen, today announced the primary analysis of the Phase I/II study evaluating the investigational use of irinotecan liposome injection (Onivyde®) in combination with 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) together, known as NALIRIFOX in study patients with previously untreated, unresectable, locally advanced and metastatic pancreatic ductal adenocarcinoma (PDAC) during a late-breaking oral presentation at the ESMO World Congress on Gastrointestinal Cancer (WCGI), 1–5 July 2020.

read article

Evelo Biosciences to Present Clinical Data from Phase 1/2 Trial of EDP1503 at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting

(AP) July 1, 2020 - Evelo Biosciences, Inc. today announced that clinical data from the Phase 1/2 open-label study of EDP1503, in combination with pembrolizumab, in patients with advanced metastatic microsatellite stable colorectal carcinoma (MSS CRC), triple-negative breast cancer (TNBC), and checkpoint inhibitor relapsed tumors, will be presented at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting being held July 1 - 4, 2020.

read article

Results in Hormone Receptor-Positive and TNBC Subgroups from the Phase III BROCADE3 Trial

(ESMO Breast Cancer 2020) May 26, 2020 - Improvement in progression-free survival reported.

read article

ESMO Breast Cancer Virtual Meeting 2020: Final Results of the LOTUS Study

(ESMO Breast Cancer 2020) May 23, 2020 - Findings from the phase II study support further evaluation of ipatasertib plus paclitaxel in patients with advanced triple-negative breast cancer.

read article

Novel Biomarkers Predict Benefit With Immunotherapy In Metastatic Breast Cancer

(ESMO Breast Cancer 2020) May 22, 2020 - Two novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic breast cancer and may help to identify the patients most likely to benefit from this treatment.

read press release

ESMO Breast Cancer Virtual Meeting 2020: Results of an Interim Analysis of the PHranceSCa Study

(ESMO Breast Cancer 2020) May 24, 2020 - Patients with HER2-positive early breast cancer prefer a subcutaneous fixed-dose combination of pertuzumab and trastuzumab over intravenous treatment.

read article

Verzenio™ (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study

(Yahoo! Finance) Oct 9, 2019 - Verzenio plus fulvestrant significantly extended life to a median of 46.7 months vs. 37.3 months compared to fulvestrant alone. MONARCH 2 showed statistically significant results for women whose disease progressed following endocrine therapy. Overall survival results were consistent across subgroups, including in women with poor prognostic factors – whose cancer quickly returned or spread to their organs, such as liver or lungs. Data presented at European Society for Medical Oncology (ESMO) 2019 Congress in the Presidential Symposium and simultaneously published in JAMA Oncology.

read article

Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019

(Yahoo! Finance) Oct 8, 2019 - Adlai Nortye Ltd. announced today at the European Society for Medical Oncology (ESMO) 2019 Congress the first results from a phase 1b neoadjuvant study of AN0025 (previously known as E7046), an investigational, potentially first in class oral EP4 antagonist.

read article

It May Be Time For Standard Breast Cancer Treatment To Change

(Forbes) Oct 3, 2019 - New trial suggests that doctor's shouldn't wait to add targeted therapy drugs to standard breast cancer treatment. Results from a clinical trial show that adding ribociclib, a targeted therapy drug, to the standard treatment plan for women with advanced hormone-receptor positive/HER2- breast cancer helps patients live longer and better quality lives. The researchers involved now believe the drug should be the first line of treatment for patients with this very common form of breast cancer.

read article

ESMO 2019 Makes For A Disappointing Read-Across To Biotech

(Vantage) Oct 2, 2019 - An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.

read article

First Prostate Cancer Therapy to Target Genes Delays Cancer Progression

(Northwestern Medicine) Sept 30, 2019 - Genetic-based treatment nearly doubles time without disease progression in metastatic prostate cancer. For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, according to a large, international phase 3 trial.

read article

Experimental Prostate Cancer Therapy Delays Disease In 'Landmark' Trial

(CNN) Sept 30, 2019 - An experimental prostate cancer therapy may change the way patients are treated for the second-deadliest cancer in men. In a "landmark" phase III clinical trial, presented at the European Society of Medical Oncology conference in Barcelona on Monday, the drug olaparib was shown to be safe and effective in delaying the progression of disease in men with both metastatic castrate-resistant prostate cancer and mutations in their homologous recombination repair, or HRR, genes.

read article

Netherlands Drug Repurposing, Tumor Profiling Trial Results Reported at ESMO

(Precision Oncology News) Sept 30, 2019 - Two genomics-centered trials in the Netherlands — the Center for Personalized Cancer Treatment (CPCT-02) and Drug Rediscovery Protocol (DRUP) — are demonstrating the potential for finding tumor genomic features that may guide treatment for advanced cancer patients, even as experts continue working on strategies for interpreting, evaluating, and communicating such findings in a clinical context. During a session on the genomic characterization of cancer cells at the European Society for Molecular Oncology Congress here yesterday, representatives from CPCT and DRUP provided updates on the Phase I trials, which are digging into genomic features influencing treatment response and molecularly guided off-label drug matching in advanced cancers, respectively.

read article (free registration required)

Lung Cancer Studies Provide Contradictory Results on Utility of TMB as Biomarker for Treatment

(Precision Oncology News) Sept 29, 2019 - In presentations at the annual meeting of the European Society for Medical Oncology in Barcelona on Friday, researchers reported seemingly contradictory results on the utility of tumor mutational burden (TMB) as a biomarker for treatment of advanced non-small cell lung cancer (NSCLC) with pembrolizumab (Merck's Keytruda).

read article (free registration required)

Elevar Announces Results From The Angel Trial, A Study Of Monotherapy Rivoceranib (Apatinib) In Late-Stage Gastric Cancer Patients

(Elevar Therapeutics) Sept 29, 2019 - Elevar Therapeutics announced data from the ANGEL trial, a randomized phase 3 study of rivoceranib (also known as apatinib) plus best supportive care in patients with gastric or gastroesophageal junction cancer who have failed at least 2 prior lines of therapy.

read corporate press release

Immunomedics Provides Corporate Update

(Immunomedics) Sept 28, 2019 - Immunomedics today presented at the European Society for Medical Oncology (ESMO) Annual Congress interim data from the 100-patient cohort of cisplatin-eligible patients of the Company’s TROPHY-U-01 open-label Phase 2 study.

read corporate press release

TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer

(Yahoo! Finance) Sept 30, 2019 - Tyme Technologies, Inc. announced that its open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral monotherapy in patients with advanced pancreatic cancer continues to demonstrate encouraging overall (OS) results and has a well-tolerated safety profile.

read article
Next Page